STAHL NEIL 1226689 Data last updated 2024-05-14 07:02:16 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-23 | 2023-08-21 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.55 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 106.74 (REGN) | ||
| 2023-08-23 | 2023-08-21 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 106.74 (REGN) | ||
| 2023-08-23 | 2023-08-21 | 2023-08-21 to 2023-08-22 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 50000.0 | 48.5 | 4.68 | 835.16 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F S | 53100.0
|
106.74 (REGN) |
| 2023-08-23 | 2023-08-21 | 2023-08-21 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | acq | 50000.0 | 48.5 | 4.68 | 399.66 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 103100.0 | 106.74 (REGN) |
| 2023-11-14 | 2023-11-10 | 2023-11-10 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 400.0 | 0.75 | 0.04 | 0.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code G | 52700.0 | 107.13 (REGN) |
| 2023-11-14 | 2023-11-10 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-11-14 | 2023-11-10 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-12 | 2023-12-08 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-12 | 2023-12-08 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.13 (REGN) | ||
| 2023-12-12 | 2023-12-08 | 2023-12-08 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | acq | 853.0 | 1.62 | 0.08 | 0.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code A | 52744.0 | 107.13 (REGN) |
| 2023-12-12 | 2023-12-08 | 2023-12-08 to 2023-12-11 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 1534.0 | 2.86 | 0.14 | 843.93 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 52019.0
|
107.13 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | acq | 30750.0 | 37.15 | 2.85 | 399.66 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code M | 82769.0 | 107.94 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 22713.0 | 27.44 | 2.1 | 956.65 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code F | 60056.0 | 107.94 (REGN) |
| 2024-02-06 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-06 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-08 | 2024-02-07 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-08 | 2024-02-07 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-08 | 2024-02-07 | 2024-02-07 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 8037.0 | 13.38 | 0.74 | 950.35 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code S | 52019.0
|
107.94 (REGN) |
| 2024-02-28 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 4605.0 | 0 | 0.43 | 0.0 | By Spouse As Trustee | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | holding | 5834.0 | 0 | 0.54 | 0.0 | By 401(K) Plan | Common Stock | REGENERON PHARMACEUTICALS, INC. | NA | 107.94 (REGN) | ||
| 2024-02-28 | 2024-02-26 | 2024-02-26 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 1020.0 | 1.96 | 0.09 | 0.0 | Direct | Common Stock | REGENERON PHARMACEUTICALS, INC. | code G | 50999.0 | 107.94 (REGN) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-23 | 2023-08-21 | 2023-08-21 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 50000.0 | 61.92 | 4.68 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 30750.0 | 106.74 (REGN) |
| 2023-12-12 | 2023-12-08 | 2023-12-08 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | acq | 3059.0 | 100.0 | 0.29 | 843.79 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code A | 3059.0 | 107.13 (REGN) |
| 2024-02-06 | 2024-02-02 | 2024-02-02 | 4 | Stahl Neil | EVP RESEARCH AND DEVELOPMENT | dsp | 30750.0 | 100.0 | 2.85 | 399.66 | Direct | Non Qualified Stock Option (Right To Buy) | REGENERON PHARMACEUTICALS, INC. | code M | 0.0 | 107.94 (REGN) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)